Cargando…

A Comparison of Different Immune Activation Strategies to Reverse HIV-1 Latency

Resting CD4+ T cells are the best characterized component of the latent reservoir. Activation of these CD4+ T cells is needed to optimize transcription and viral replication, and this strategy has been used to measure the inducible reservoir. There are several methods that can be used to activate CD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garliss, Caroline C, Kwaa, Abena K, Blankson, Joel N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139987/ https://www.ncbi.nlm.nih.gov/pubmed/32284948 http://dx.doi.org/10.1093/ofid/ofaa082

Ejemplares similares

Viral reservoirs in elite controllers of HIV-1 infection: Implications for HIV cure strategies
por: Woldemeskel, Bezawit A., et al.
Publicado: (2020)

A T Cell Receptor Sequencing-Based Assay Identifies Cross-Reactive Recall CD8(+) T Cell Clonotypes Against Autologous HIV-1 Epitope Variants
por: Chan, Hok Yee, et al.
Publicado: (2020)

The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells
por: Kwaa, Abena K., et al.
Publicado: (2017)

Combined Effects of HLA-B*57/5801 Elite Suppressor CD8+ T Cells and NK Cells on HIV-1 Replication
por: May, Megan E., et al.
Publicado: (2020)

CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection
por: Veenhuis, Rebecca T., et al.
Publicado: (2021)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

The Effect of Latency Reversal Agents on Primary CD8 + T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
por: Walker-Sperling, Victoria E., et al.
Publicado: (2016)

Proviral location affects cognate peptide–induced virus production and immune recognition of HIV-1–infected T cell clones
por: Dragoni, Filippo, et al.
Publicado: (2023)

A CD3/CD28 microbead-based HIV-1 viral outgrowth assay
por: Kuzmichev, Yury V, et al.
Publicado: (2017)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
por: Woldemeskel, Bezawit A, et al.
Publicado: (2021)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation
por: Ezeonwumelu, Ifeanyi Jude, et al.
Publicado: (2022)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

CD4(+) T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses
por: Woldemeskel, Bezawit A., et al.
Publicado: (2022)

Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection
por: Schnittman, Samuel R, et al.
Publicado: (2021)

Tracking HIV Rebound following Latency Reversal Using Barcoded HIV
por: Marsden, Matthew D., et al.
Publicado: (2020)

Diverse effects of interferon alpha on the establishment and reversal of HIV latency
por: Van der Sluis, Renée M., et al.
Publicado: (2020)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
por: Meås, Hany Zekaria, et al.
Publicado: (2020)

A truncated HIV Tat demonstrates potent and specific latency reversal activity
por: Van Gulck, Ellen, et al.
Publicado: (2023)

Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies
por: Delannoy, Aurélie, et al.
Publicado: (2019)

HIV cure trial mergers: Spotlighting the epigenetics of latency reversal
por: Denton, Paul W.
Publicado: (2022)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies
por: Khanal, Sushant, et al.
Publicado: (2021)

Relevance of multiply spliced HIV-1 RNA measurement in assessing the efficacy of viral latency-reversing strategies
por: Doria, Margherita
Publicado: (2021)

Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV
por: Zanni, Markella V, et al.
Publicado: (2017)

Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells
por: Alvarez-Carbonell, David, et al.
Publicado: (2017)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Bioactive Compounds from Euphorbia usambarica Pax. with HIV-1 Latency Reversal Activity
por: Tsai, Yu-Chi, et al.
Publicado: (2021)

HIV Latency and Nanomedicine Strategies for Anti-HIV Treatment and Eradication
por: Andre, Mickensone, et al.
Publicado: (2023)

“Is a Bird in the Hand Worth 5 in the Bush?”: A Comparison of 3 Data-to-Care Referral Strategies on HIV Care Continuum Outcomes in San Francisco
por: Sachdev, Darpun D, et al.
Publicado: (2020)

Innate immune regulation in HIV latency models
por: Olson, Rebecca M., et al.
Publicado: (2022)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Cleavage and Polyadenylation Specificity Factor 6 Is Required for Efficient HIV-1 Latency Reversal
por: Zheng, Yue, et al.
Publicado: (2021)

Partial Normalization of Biomarkers of Inflammation and Immune Activation Among Virally Suppressed Men With HIV Infection and High ART Adherence
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2020)

Residual Central Nervous System Immune Activation Is Not Prevented by Antiretroviral Therapy Initiated During Early Chronic HIV Infection
por: Edén, Arvid, et al.
Publicado: (2023)

Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States
por: Zanni, Markella V, et al.
Publicado: (2022)

Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems
por: Bialek, Julia K., et al.
Publicado: (2016)

HIV-1 latency in activated T-cells
por: Berkhout, Ben
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_phsb3d03rq96ch46mb5bme6c12